Century Therapeutics Inc
IPSC
查看详细走势图
1.700USD
+0.030+1.80%
收盘 02/06, 16:00（美东）报价延迟15分钟
147.10M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.80%
5天
-10.53%
1月
+30.77%
6月
+221.24%
今年开始到现在
+70.89%
1年
+134.35%
查看详细走势图
TradingKey Century Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Century Therapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名97/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价4.12。中期看，股价处于上升通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Century Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Century Therapeutics Inc亮点
亮点风险
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.
业绩高增长
公司营业收入稳步增长，连续3年增长26.74%
业绩增长期
公司处于发展阶段，最新年度总收入6.59M美元
估值低估
公司最新PE估值-5.42，处于3年历史低位
机构减仓
最新机构持股33.92M股，环比减少26.09%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值2.59M
活跃度降低
近期活跃度降低，过去20天平均换手率0.49
分析师目标
根据
5
位分析师
买入
评级
4.120
目标均价
+130.17%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Century Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Century Therapeutics Inc简介
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.
公司代码IPSC
公司Century Therapeutics Inc
CEOPfeiffenberger (Brent)
网址https://www.centurytx.com/
相关品种
